What does AUDOPHARMA do?

AUDOPHARMA is a pharmacy in De Panne. Private Limited, started on 26 November 1981, 1 establishment.

What is the address of AUDOPHARMA?

The registered office of AUDOPHARMA is located at Dorpsstraat 2, 8660 De Panne.

Is AUDOPHARMA still active?

Yes. According to the CBE (30 October 2026) AUDOPHARMA is active, legal situation “Normale toestand”, started on 26 November 1981.

Is AUDOPHARMA registered on Peppol?

Yes, AUDOPHARMA is registered on the Peppol network with ID 0208:0422153995.

What is the enterprise number of AUDOPHARMA?

The enterprise number of AUDOPHARMA is BE0422153995.

When was AUDOPHARMA founded?

AUDOPHARMA was founded on 26 November 1981.

Who are the directors of AUDOPHARMA?

According to the 2025 annual accounts, the directors of AUDOPHARMA are: Phar West BV.

Is AUDOPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 November 1981; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did AUDOPHARMA make in 2025?

AUDOPHARMA posted a profit after taxes of € 43,610 in financial year 2025.

What is the revenue of AUDOPHARMA?

As a small company, AUDOPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 114,780.

How many employees does AUDOPHARMA have?

According to the 2025 annual accounts, AUDOPHARMA has 0.9 full-time equivalents (FTE).

AUDOPHARMA (Private Limited) - De Panne - BE0422153995

Dossier AUDOPHARMA, printed on 30 October 2026 from databakkes.be/en/0422153995/audopharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

AUDOPHARMA from De Panne, company number BE0422153995, closed financial year 2025 with a result of € 43,610 after tax. For that financial year AUDOPHARMA recorded a gross margin of € 114,780 and equity of € 233,319. Compared with financial year 2024, the result moved from € 67,769 to € 43,610. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.

What it is worth Growing

€ 233,319

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 43,610

▼ 36% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 131,988

▲ 2% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 41,000 paid out

94 % of the profit went to the shareholders, mostly to PHAR WEST (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

0.9

▲ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 53,247

▲ 51% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,963

▼ 28% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 52,000

▼ 20% vs 2024

€ 13,000 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 145,649

▲ 73% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 5,004

▼ 44% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 116,892 Gross margin 2022: € 116,892 First fiscal year in the series	€ 123,251 Gross margin 2023: € 123,251 ▲ 5% vs 2022 (€ 116,892) Favourable step	€ 121,653 Gross margin 2024: € 121,653 ▼ 1% vs 2023 (€ 123,251) Unfavourable step	€ 114,780 Gross margin 2025: € 114,780 ▼ 6% vs 2024 (€ 121,653) Unfavourable step	▼ 6%
Profit after taxes	€ 68,191 Profit after taxes 2022: € 68,191 First fiscal year in the series	€ 73,102 Profit after taxes 2023: € 73,102 ▲ 7% vs 2022 (€ 68,191) Favourable step	€ 67,769 Profit after taxes 2024: € 67,769 ▼ 7% vs 2023 (€ 73,102) Unfavourable step	€ 43,610 Profit after taxes 2025: € 43,610 ▼ 36% vs 2024 (€ 67,769) Unfavourable step	▼ 36%
Equity	€ 232,338 Equity 2022: € 232,338 First fiscal year in the series	€ 232,940 Equity 2023: € 232,940 Unchanged (€ 232,338) Favourable step	€ 230,709 Equity 2024: € 230,709 ▼ 1% vs 2023 (€ 232,940) Unfavourable step	€ 233,319 Equity 2025: € 233,319 ▲ 1% vs 2024 (€ 230,709) Favourable step	▲ 1%
Total debts	€ 191,543 Total debts 2022: € 191,543 First fiscal year in the series	€ 197,532 Total debts 2023: € 197,532 ▲ 3% vs 2022 (€ 191,543) Unfavourable step	€ 233,765 Total debts 2024: € 233,765 ▲ 18% vs 2023 (€ 197,532) Unfavourable step	€ 249,764 Total debts 2025: € 249,764 ▲ 7% vs 2024 (€ 233,765) Unfavourable step	▲ 7%
Cash	€ 110,844 Cash 2022: € 110,844 First fiscal year in the series	€ 90,072 Cash 2023: € 90,072 ▼ 19% vs 2022 (€ 110,844) Unfavourable step	€ 129,124 Cash 2024: € 129,124 ▲ 43% vs 2023 (€ 90,072) Favourable step	€ 131,988 Cash 2025: € 131,988 ▲ 2% vs 2024 (€ 129,124) Favourable step	▲ 2%
Land & buildings	€ 4,402 Land & buildings 2022: € 4,402 First fiscal year in the series	€ 3,400 Land & buildings 2023: € 3,400 ▼ 23% vs 2022 (€ 4,402) Unchanged	€ 2,987 Land & buildings 2024: € 2,987 ▼ 12% vs 2023 (€ 3,400) Unchanged	€ 2,575 Land & buildings 2025: € 2,575 ▼ 14% vs 2024 (€ 2,987) Unchanged	▼ 14%
Retained profit	€ 207,538 Retained profit 2022: € 207,538 First fiscal year in the series	€ 208,140 Retained profit 2023: € 208,140 Unchanged (€ 207,538) Favourable step	€ 205,909 Retained profit 2024: € 205,909 ▼ 1% vs 2023 (€ 208,140) Unfavourable step	€ 208,519 Retained profit 2025: € 208,519 ▲ 1% vs 2024 (€ 205,909) Favourable step	▲ 1%
Dividend	€ 68,000 Dividend 2022: € 68,000 First fiscal year in the series	€ 72,500 Dividend 2023: € 72,500 ▲ 7% vs 2022 (€ 68,000) Unchanged	€ 70,000 Dividend 2024: € 70,000 ▼ 3% vs 2023 (€ 72,500) Unchanged	€ 41,000 Dividend 2025: € 41,000 ▼ 41% vs 2024 (€ 70,000) Unchanged	▼ 41%
Bank debt	€ 91,000 Bank debt 2022: € 91,000 First fiscal year in the series	€ 78,000 Bank debt 2023: € 78,000 ▼ 14% vs 2022 (€ 91,000) Favourable step	€ 65,000 Bank debt 2024: € 65,000 ▼ 17% vs 2023 (€ 78,000) Favourable step	€ 52,000 Bank debt 2025: € 52,000 ▼ 20% vs 2024 (€ 65,000) Favourable step	▼ 20%
Balance sheet total	€ 423,882 Balance sheet total 2022: € 423,882 First fiscal year in the series	€ 430,472 Balance sheet total 2023: € 430,472 ▲ 2% vs 2022 (€ 423,882) Unchanged	€ 464,474 Balance sheet total 2024: € 464,474 ▲ 8% vs 2023 (€ 430,472) Unchanged	€ 483,083 Balance sheet total 2025: € 483,083 ▲ 4% vs 2024 (€ 464,474) Unchanged	▲ 4%
Employees (FTE)	0.8 Employees (FTE) 2022: 0.8 First fiscal year in the series	0.8 Employees (FTE) 2023: 0.8 Unchanged (0.8) Unchanged	0.8 Employees (FTE) 2024: 0.8 Unchanged (0.8) Unchanged	0.9 Employees (FTE) 2025: 0.9 ▲ 0.1 vs 2024 (0.8) Unchanged	▲ 0.1

Key figures of AUDOPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AUDOPHARMA?

What happened at AUDOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 7, 2026 New annual accounts for financial year 2025: profit of € 43,610 (▼ 36% vs 2024). Source: NBB ↗
Nov 26, 1981 Start of the company according to the CBE. KBO
Nov 1, 1981 New establishment in De Panne. KBO

In short

From € 68,191 profit in 2022 to € 43,610 profit in 2025.

Paid € 3,834 in corporate taxes since 2022.

Best year ever: 2023, with € 73,102 profit.

Paid out € 251,500 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

PHAR WEST 99.9%

The stake of PHAR WEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

AUDOPHARMA

Behind AUDOPHARMA is Phar West BV. The shares are held by PHAR WEST (99.9%).

Directors

According to the 2025 annual accounts

Phar West BV

Director · represented by Tine Wouters

Shareholders

PHAR WEST

99.9%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Dorpsstraat 2

8660 De Panne

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

PHAR WEST same network

€ 220,643 gross margin · 2025

Groep De Medicijnnatie

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0422.153.995

VAT number

BE 0422.153.995

Registered office

Dorpsstraat 2, 8660 De Panne

Names & denominations

AUDOPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

26 November 1981

Peppol

Active · Active since 14 May 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

AUDOPHARMA

Financials

What happened to AUDOPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions